Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial

[1]  J. Mascola,et al.  Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase , 2021, The New England journal of medicine.

[2]  J. Mascola,et al.  Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates , 2021, Science.

[3]  F. Blanquart,et al.  Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community, France, June to July 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[4]  E. Klein,et al.  Infection with the SARS-CoV-2 Delta Variant is Associated with Higher Infectious Virus Loads Compared to the Alpha Variant in both Unvaccinated and Vaccinated Individuals , 2021, medRxiv.

[5]  J. Mascola,et al.  Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants , 2021, Science.

[6]  V. Lee,et al.  Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study , 2021, Clinical Microbiology and Infection.

[7]  Samuel M. Brown,et al.  Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States , 2021, medRxiv.

[8]  O. Mor,et al.  Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[9]  Andrew L. Phillips,et al.  Prevention and Attenuation of COVID-19 by BNT162b2 and mRNA-1273 Vaccines , 2021, medRxiv.

[10]  S. Hasnain,et al.  SARS-CoV-2 variants of concern are emerging in India , 2021, Nature Medicine.

[11]  G. Biele,et al.  Estimating infectiousness throughout SARS-CoV-2 infection course , 2021, Science.

[12]  N. Andrews,et al.  Effectiveness of COVID-19 vaccines against the B.1.617.2 variant , 2021, medRxiv.

[13]  Samuel M. Brown,et al.  Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[14]  D. Moodley,et al.  Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant , 2021, The New England journal of medicine.

[15]  L. Abu-Raddad,et al.  Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants , 2021, The New England journal of medicine.

[16]  S. Elbashir,et al.  Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice , 2021, bioRxiv.

[17]  R. Kishony,et al.  Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine , 2021, Nature Medicine.

[18]  S. Madhi,et al.  Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant , 2021, The New England Journal of Medicine.

[19]  R. Samworth,et al.  Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection , 2021, eLife.

[20]  N. Sullivan,et al.  Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine - Preliminary Report. , 2021, The New England journal of medicine.

[21]  P. Dormitzer,et al.  Neutralizing Activity of BNT162b2-Elicited Serum - Preliminary Report. , 2021, The New England journal of medicine.

[22]  A. Hidalgo-Miranda,et al.  Saliva is a reliable and accessible source for the detection of SARS-CoV-2 , 2021, International Journal of Infectious Diseases.

[23]  Mi-Kyung Lee,et al.  Duration of Culturable SARS-CoV-2 in Hospitalized Patients with Covid-19 , 2021, The New England journal of medicine.

[24]  B. Graham,et al.  mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants , 2021, bioRxiv.

[25]  N. Dendukuri,et al.  Comparison of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection of SARS-CoV-2: A Systematic Review and Meta-analysis. , 2021, JAMA internal medicine.

[26]  J. Campbell,et al.  The Sensitivity and Costs of Testing for SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs , 2021, Annals of Internal Medicine.

[27]  M. Yin,et al.  Pretest Symptom Duration and Cycle Threshold Values for Severe Acute Respiratory Syndrome Coronavirus 2 Reverse-Transcription Polymerase Chain Reaction Predict Coronavirus Disease 2019 Mortality , 2021, Open forum infectious diseases.

[28]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[29]  Ye Li,et al.  Prevalence of Co-Infections with Respiratory Viruses in Individuals Investigated for SARS-CoV-2 in Ontario, Canada , 2020, Viruses.

[30]  C. Tebé,et al.  Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study , 2020, The Lancet Infectious Diseases.

[31]  Sonia N. Rao,et al.  A Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19 , 2020, Infectious Diseases and Therapy.

[32]  Edward C. Holmes,et al.  A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology , 2020, Nature Microbiology.

[33]  Fayzan F. Chaudhry,et al.  SARS-CoV-2 viral load predicts COVID-19 mortality , 2020, The Lancet Respiratory Medicine.

[34]  W. Lim,et al.  Co-infections in people with COVID-19: a systematic review and meta-analysis , 2020, Journal of Infection.

[35]  N. Shah,et al.  Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens. , 2020, JAMA.

[36]  Malik Peiris,et al.  Viral dynamics in mild and severe cases of COVID-19 , 2020, The Lancet Infectious Diseases.

[37]  Eric H. Y. Lau,et al.  Temporal dynamics in viral shedding and transmissibility of COVID-19 , 2020, Nature Medicine.

[38]  M. Okano,et al.  Cohort Study , 2020, Definitions.

[39]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[40]  Stefan Elbe,et al.  Data, disease and diplomacy: GISAID's innovative contribution to global health , 2017, Global challenges.